Single-molecule PCR analysis of germ line mutation induction by anticancer drugs in mice

Colin D Glen1, Andrew G Smith, Yuri E Dubrova

  • 1Department of Genetics and Medical Research Council Toxicology Unit, University of Leicester, Leicester, United Kingdom.

Cancer Research
|May 17, 2008
PubMed

Insights

A new single-molecule PCR method efficiently monitors germ line mutations caused by chemical mutagens and anticancer drugs. This approach uses fewer mice and detects genetic hazards at clinically relevant exposure levels.

Area of Science:

  • Genetics
  • Toxicology
  • Molecular Biology

Background:

  • Assessing genetic hazards from chemical mutagens and anticancer drugs is crucial for human health.
  • Existing methods for monitoring germ line mutations can be resource-intensive.

Purpose of the Study:

  • To validate a single-molecule PCR approach for detecting mutation induction at the mouse expanded simple tandem repeat (ESTR) locus Ms6-hm.
  • To evaluate the genetic effects of ethylnitrosourea and four anticancer drugs (bleomycin, cyclophosphamide, mitomycin C, procarbazine) on mouse germ line mutations.

Main Methods:

  • Utilized a single-molecule PCR-based assay to quantify ESTR mutation frequencies.
  • Exposed male mice to varying doses of ethylnitrosourea, bleomycin, cyclophosphamide, mitomycin C, and procarbazine.
  • Compared mutation frequencies in treated mice to control groups.

Main Results:

  • The single-molecule PCR method demonstrated a dose-response for ethylnitrosourea-induced mutations similar to previous studies.
  • Clinically relevant doses of bleomycin, cyclophosphamide, and mitomycin C significantly increased ESTR mutation frequencies in a dose-dependent manner.
  • Procarbazine exposure showed a dose-dependent increase in mutation frequency, plateauing at higher concentrations.

Conclusions:

  • The single-molecule PCR technique is an efficient and novel system for monitoring the genetic effects of anticancer drugs.
  • This method can detect increased mutation rates at clinically relevant exposure doses.
  • The approach significantly reduces the number of animals required for germ line mutation studies.